Navigation Links
U.S. District Court Rules from Bench in Lilly's Favor, Confirms Validity of Alimta Patent
Date:11/15/2010

INDIANAPOLIS, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the trial on the validity of the compound patent for Alimta® (pemetrexed for injection) before the U.S. District Court for the District of Delaware ended this afternoon with a ruling from the court that judgment would be entered in Lilly's favor, thereby upholding the patent's validity. The decision came in the case of Eli Lilly and Company et al v. Teva Parenteral Medicines Inc., et al. The patent provides protection for Alimta until July of 2016.

"We are pleased that the District Court has now confirmed the validity of Alimta's compound patent," said Robert A. Armitage, senior vice president and general counsel for Lilly. "We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially.  There can be no assurance that the company will prevail in any appeal.  Also, the company cannot predict whether generic pemetrexed will be marketed prior to the resolution of this litigation.  Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Alimta® (pemetrexed, Lilly)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. German District Court Finds RENASYS™ GO NPWT System Non-infringing
2. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
3. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical
6. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
7. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
8. U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly
9. Supreme Court of Israel Rules in Favor of Sun Pharma
10. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
11. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... 2017  CVS Pharmacy, the retail division of ... store design to enhance the retail customer experience ... products and expanded beauty selections paired with informational ... new offerings. Together with its innovative digital programs, ... customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... PARIS , April 20, 2017 ... EyeCET platform, the first non-viral gene expression technology that ... in the eye to address a wide range of ... UK Medicines and Healthcare products Regulatory Agency (MHRA) to ... ...
Breaking Medicine Technology:
(Date:4/23/2017)... ... April 23, 2017 , ... Altura Communication Solutions, a nationwide ... Select certification and SMB specialization. Altura is now qualified to sell, install ... the Select Certification, Altura fulfilled the training and exam requirements for the Cisco ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... named PROSHRED® Security of Philadelphia its “Woman-Owned Small Business of the ... in providing information destruction , recycling, and compliance services to businesses ...
(Date:4/22/2017)... ... April 22, 2017 , ... ... role as Vice President of Sales and Business Development at OAKWORKS, Inc. ... partner engagements, business development, and strategic planning for the company. Recognized industry-wide ...
(Date:4/21/2017)... ... 21, 2017 , ... An April 10 article in the Daily ... reveal a great deal about prehistoric ice-age dental practitioners and their primitive and, no ... to remove decayed dental matter, and that teeth were then filled with bitumen, a ...
(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
Breaking Medicine News(10 mins):